Tadalafil Tablet, Film Coated
Product Images NDC 71335-1620

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1620). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351620)

Label for Tadalafil 10 mg tablet by Bryant Ranch Prepack, NDC 71335-1620, in a package of 30 tablets. The label compares the product to Cialis 10 mg tablet by Intas Pharmaceuticals Limited and includes storage instructions to keep at 20°-25°C (68°-77°F). It also advises to keep all drugs out of reach of children and notes that the tablet is yellow, oval, with imprint FJ3.*

FDA Label Image

Figure (Tadalafil Figure1)

A set of four line graphs showing the difference in blood pressure (BP) between Tadalafil and placebo over time measured in hours (0 to 96). The graphs depict standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with the y-axis showing the difference in mmHg. Each graph includes error bars indicating variability at each time point.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs showing standing and supine systolic blood pressure (BP) changes over 24 hours post-dose. The upper graph displays standing systolic BP and the lower graph shows supine systolic BP changes. Each graph compares Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg, plotting BP (mmHg) on the vertical axis against time after dosing (hours) on the horizontal axis.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph showing the effect of tadalafil or placebo on systolic blood pressure (mmHg) over 12 hours after administration. The graph compares four groups: 20 mg tadalafil at 08:00 plus 8 mg doxazosin, placebo at 08:00 plus 8 mg doxazosin, 20 mg tadalafil at 20:00 plus 8 mg doxazosin, and placebo at 20:00 plus 8 mg doxazosin, with systolic blood pressure changes plotted against time after dosing.*

FDA Label Image

Figure (Tadalafil Figure4)

A pharmacokinetic line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The y-axis represents plasma tadalafil concentration with error bars, and the x-axis represents time up to 120 hours.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph showing the change from baseline in IPSS total score over duration of treatment in weeks. It compares tadalafil 5 mg and placebo, with tadalafil showing a greater decrease in score over 12 weeks. The graph includes statistically significant differences marked at 12 weeks (p<0.01).*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration for tadalafil 5 mg versus placebo. The graph shows greater reductions in IPSS scores with tadalafil compared to placebo, with data points at 0, 1, 4, 8, and 12 weeks. A significance level of p<0.01 is indicated.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph comparing the least-squares mean change from baseline over 26 weeks of therapy between Tadalafil/Finasteride and Placebo/Finasteride groups. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows change from baseline, with specific marked points indicating statistical significance (p<0.001 and p<0.05) for differences between groups.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment. The graph shows two lines: one for tadalafil 5 mg and one for placebo, with tadalafil demonstrating a greater decrease in IPSS Total Score compared to placebo over time. The x-axis represents the duration of treatment in weeks, and the y-axis represents the change in IPSS Total Score from baseline.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure of tadalafil, showing its molecular composition with characteristic aromatic rings, amide groups, and methylene bridges as represented in a skeletal formula diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.